A Phase I study of DLYE5953A, an anti-LY6E antibody covalently linked to monomethyl auristatin E, in patients with refractory solid tumors.

CONCLUSIONS: DLYE5953A administered at 2.4 mg/kg has acceptable safety. Preliminary evidence of anti-tumor activity in HER2-negative MBC and NSCLC patients supports further investigation of LY6E as a therapeutic target.
PMID: 32694157 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 20, 2020 Category: Cancer & Oncology Authors: Tolaney SM, Do KT, Eder JP, LoRusso PM, Weekes CD, Chandarlaplaty S, Chang CW, Chen SC, Nazzal D, Schuth E, Brunstein F, Carrasco-Triguero M, Darbonne W, Giltnane JM, Flanagan WM, Commerford SR, Ungewickell A, Shapiro GI, Modi S Tags: Clin Cancer Res Source Type: research